We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Tests to Enable Early Identification of Cognitive Decline and Personalized Treatments

By LabMedica International staff writers
Posted on 01 Dec 2023
Print article
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)
Image: Newly identified biomarkers may detect early cognitive decline via a blood test (Photo courtesy of 123RF)

Some individuals who have endured extreme stressors like psychiatric disorders or childhood abuse and neglect can experience a variety of health issues later in life, such as depression, anxiety, and cardiovascular disease. While not everyone who suffers from extreme stressors faces health complications later in life, a significant number do. For those affected, their cells tend to age more rapidly, leading to earlier physical breakdowns in the body, a phenomenon known as "accelerated biological aging." Natural aging processes typically involve a decline in cognitive functions, including memory, reasoning, executive function, and processing speed. Although global genetic research has generated mixed findings on whether accelerated biological aging kicks off early cognitive decline, previous studies suggest that early signs of cognitive decline can be identified long before they impact the quality of life. This opens up a window for early detection and intervention.

Now, a new study by researchers at Penn State (University Park, PA, USA) has unveiled genetic markers that could potentially forecast cognitive decline. According to the researchers, future blood tests might be able to detect early cell aging caused by these stressors, indicating a decline in cognitive abilities. In their study, the researchers analyzed two distinct population groups and found that accelerated biological aging might be a useful biomarker for identifying cognitive decline.

Utilizing blood samples and other medical data compiled from other studies, the researchers explored the relationship between potential genetic markers of cognitive performance, actual cognitive testing results, and the history of psychiatric disorders or childhood maltreatment. Their analysis revealed that accelerated biological aging is linked to reduced cognitive abilities and slower processing speed. However, the exact genetic markers indicating this relationship varied between the two study groups. The researchers attribute these differences to the distinct designs of the studies, suggesting that varying genetic markers could signal cognitive decline depending on the study's structure and focus.

“Understanding the connection between accelerated biological aging and cognitive decline may help researchers create treatments that help people who have experienced extreme stressors to experience better health,” said John Felt, assistant research professor in the Center for Healthy Aging and lead author of the study. “Cognitive decline can undermine your personal and professional life, especially for people who also have a psychiatric condition. Our research could lead to blood tests for early identification of cognitive decline and eventually to personalized treatments that support cognitive function in people with accelerated biological aging.”

Related Links:
Penn State 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: The mass spectrometer can detect different structures of the sugar molecules, called glycans, in cells (Photo courtesy of Lundbergs forskningsstiftelse/Magnus Gotander)

AI Model Detects Cancer at Lightning Speed through Sugar Analyses

Glycans, which are structures made up of sugar molecules within cells, can be analyzed using mass spectrometry. This technique is particularly useful because these sugar structures can reveal the presence... Read more

Hematology

view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more

Pathology

view channel
Image: The new test helps differentiate a B-cell cancer from a normal, reactive immune response (Photo courtesy of Roche)

New Highly-Sensitive Test to Help More Easily Diagnose B-Cell Lymphoma

B-cell lymphoma, a cancer primarily originating in the lymphatic system, represents about 85% of non-Hodgkin lymphoma (NHL) diagnoses. NHL ranks as the tenth most prevalent cancer globally, claiming over... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.